Financial Contrast: Aimmune Therapeutics (AIMT) & Advanced Accelerator Applications (AAAP)
Aimmune Therapeutics (NASDAQ: AIMT) and Advanced Accelerator Applications (NASDAQ:AAAP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Earnings and Valuation
This table compares Aimmune Therapeutics and Advanced Accelerator Applications’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aimmune Therapeutics||N/A||N/A||-$106.22 million||($2.25)||-10.15|
|Advanced Accelerator Applications||$134.75 million||16.39||-$14.53 million||($0.88)||-56.93|
Advanced Accelerator Applications has higher revenue and earnings than Aimmune Therapeutics. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Aimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Aimmune Therapeutics has a beta of -1.1, meaning that its stock price is 210% less volatile than the S&P 500. Comparatively, Advanced Accelerator Applications has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
Insider & Institutional Ownership
72.9% of Aimmune Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Advanced Accelerator Applications shares are owned by institutional investors. 24.6% of Aimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Aimmune Therapeutics and Advanced Accelerator Applications’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Applications||-33.83%||-16.05%||-11.18%|
This is a breakdown of recent ratings and target prices for Aimmune Therapeutics and Advanced Accelerator Applications, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Applications||0||1||4||0||2.80|
Aimmune Therapeutics presently has a consensus target price of $36.67, suggesting a potential upside of 60.61%. Advanced Accelerator Applications has a consensus target price of $56.50, suggesting a potential upside of 12.77%. Given Aimmune Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Aimmune Therapeutics is more favorable than Advanced Accelerator Applications.
Advanced Accelerator Applications beats Aimmune Therapeutics on 7 of the 12 factors compared between the two stocks.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
About Advanced Accelerator Applications
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.